| abstract |
A pharmaceutical composition comprising, as a first active agent, 6β, 7β; 15β, 16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to one daily dose, after administration of the composition, from about 2 mg to about 4 mg, and, as another active agent, 17α-ethinyl estradiol (ethinyl estradiol) in an amount corresponding to a daily dose of about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or neutral excipients. In one particular embodiment, the composition comprises a plurality of separately packaged and individually separable daily dosage units arranged in a single package and intended for oral administration for at least 21 consecutive days, said daily dosage units containing each combination of drospirenone and ethinyl estradiol. The composition may further comprise 7 or fewer daily dosage units which do not contain any active agent or contain ethinyl estradiol alone. |